Recovery
Glepaglutide
Also called ZP1848
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Quick start
Glepaglutide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 10–10 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~10.4 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Glepaglutide describe 10–10 mg per administration. Descriptive only, not a recommendation.
Roughly two days from limited reports; the figure is thin and estimates vary.
Dosing schedule
How Glepaglutide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported doseThe long half-life supports weekly spacing; the EASE program ran 10 mg once or twice weekly. | 10 mg | Once or twice weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.08× single dose
- Time to steady state
- 10.4days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Naimi RM et al., Lancet Gastroenterology & Hepatology 2019 (EASE-1)Subcutaneous glepaglutide (ZP1848) assessed for intestinal absorption in short-bowel syndrome; the later EASE program used 10 mg once or twice weekly.